The authors thank Robert Kim, An Song, and Kenneth Glasscock for review of the manuscript and to David Suhy for oversight and management of the African green monkey R100-GFP study. They also thank Charles River Laboratories, Valley Biosystems, and Virscio, Inc., for technical assistance with the in vivo studies.
Author Contributions: M.A.C., R.H.C., C.B., T.V., M.L., J.H., G.B., M.K., D.S., P.F., and D.K. conceived and designed the experiments. R.H.C., C.B., T.V., P.S., C.S., A.K., M.Q., and M.H. performed the experiments. M.A.C., R.H.C., C.B., T.V., P.S., C.S., A.K., M.L., M.Q., A.M.K., and M.H. analyzed the data. K.B., D.K., T.M., and K.D. contributed materials/analysis tools. M.A.C., R.H.C., P.F., and D.K. wrote the paper.
Disclosure: M.A. Calton, 4DMT (E, I) and is an inventor on the following relevant international patent filings assigned to 4DMT (P): PCT/US2022/026395; R.H. Croze, 4DMT (E, I); C. Burns, 4DMT, (I); and former employee at 4DMT, and is an inventor on the following relevant international patent filings assigned to 4DMT (P): PCT/US2022/026395; G. Beliakoff None; T. Vazin, 4DMT (I) and former employee at 4DMT; P. Szymanksi, 4DMT, (I); and former employee at 4DMT and is an inventor on the following relevant international patent filings assigned to 4DMT (P): PCT/US2022/026395 and WO2019104279A1; C. Schmitt, former employee at 4DMT, has unvested stock options and is a current employee at Codexis Inc. (E, I); A. Klein, 4DMT (I) and former employee at 4DMT; M. Leong, 4DMT, (P, I) and former employee at 4DMT; M. Quezada, 4DMT (E, I); J. Holt, 4DMT (I) and former employee at 4DMT; G. Bolender, 4DMT (I) and former employee at 4DMT; K. Barglow, 4DMT (E, I); D. Khoday, 4DMT (E, I); T. Mason, 4DMT (E, I); K. Delaria, 4DMT (E, I); M. Hassanipour, is a former employee at 4DMT (I); M. Kotterman, former employee at 4DMT (I), and is an inventor on the following relevant international patent filings assigned to 4DMT (P): WO2017197355A2 and WO2019104279A1; A.M. Khanani, has served as a consultant to and/or received research support from 4DMT (C, F), AbbVie (C, F), Adverum (C, F), Alcon (C, F), Alexion (C, F), Amgen (C, F), Annexin (C, F), Annexon (C, F), Apellis Pharmaceuticals (C, F), Aviceda Therapeutics (C, F), Beacon Therapeutics (C, F), Clearside Biomedical (C, F), Complement Therapeutics (C, F), Exegenesis (C, F), EyePoint Pharmaceuticals (C, F), Fronterra Therapeutics (C, F), Genentech (C, F), Gyroscope Therapeutics (C, F), i-Lumen Scientific (C, F), Iveric Bio (C, F), Janssen Pharmaceuticals (C, F), Kodiak Sciences (C, F), Kriya Therapeutics (C, F), Nanoscope (C, F), Neurotech (C, F), Novartis (C, F), Ocular Therapeutix (C, F), Oculis (C, F), Ocuphire (C, F), OcuTerra (C, F), Olive BioPharma (C, F), Opthea (C, F), Oxular (C, F), Oxurion (C, F), Perfuse (C, F), Ray Therapeutics (C, F), Recens Medical (C, F), Regeneron Pharmaceuticals (C, F), Regenxbio (C, F), Revive (C, F), RevOpsis (C, F), Roche (C, F), Sanofi (C, F), Stealth BioTherapeutics (C, F), Thea Pharma (C, F), Unity Biotechnology (C, F), Vanotech (C, F), Vial (C, F), and Unity Biotechnology (C, F); Aviceda Therapeutics (I), Oculis (I), PolyPhotonix (I), Recens Medical (I), Perfuse (I), RevOpsis (I), and Vial (I); D. Schaffer, 4DMT (C, I), has received sponsored research funding from 4DMT (F), and is an inventor on the following relevant international patent filings assigned to 4DMT (P): WO2017197355A2 and WO2019104279A1; P. Francis, former employee at 4DMT (I), and is an inventor on the following relevant international patent filing assigned to 4DMT (P): WO2019104279A1; D. Kirn, is the chief executive officer at 4DMT with salary, bonus, stock and stock options, and is an inventor on the following relevant international patent filings assigned to 4DMT (P): WO2017197355A2 and WO2019104279A1